EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Monoclonal anti-CD20 antibody rituximab is safe and efficient in patients with CD20-positive Hodgkins lymphoma



Monoclonal anti-CD20 antibody rituximab is safe and efficient in patients with CD20-positive Hodgkins lymphoma



Onkologie 23(Sonderheft 7): 147, October




(PDF emailed within 1 workday: $29.90)

Accession: 035339546

Download citation: RISBibTeXText



Related references

Monoclonal anti-CD20 antibody rituximab for treatment of CD20-positive Hodgkins lymphoma The German experience. Blood 96(11 Part 1): 729a, November 16, 2000

Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Pediatric Hematology and Oncology 23(8): 661-666, 2006

The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkins lymphoma cell lines. Blood 88(10 SUPPL 1 PART 1-2): 637A, 1996

Y-90 anti-CD20 monoclonal antibody dosimetry calculated from In-111 anti-CD20 in patients with low and intermediate grade B-cell non-Hodgkins lymphoma. Journal of Nuclear Medicine 38(5 SUPPL ): 251P, 1997

Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatric Hematology and Oncology 20(4): 339-344, 2003

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Chinese Journal of Cancer Research 28(2): 197-208, 2016

Multicenter randomized phase II study of the monoclonal anti-CD20 antibody Rituximab in patients with intermediate/high grade non-Hodgkins lymphoma. Annals of Hematology 77(SUPPL 2): S180, 1998

Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Archives of Dermatology 137(3): 269-272, 2001

Tolerance and pharmacodynamics phase Ⅰ clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Zhonghua Xue Ye Xue Za Zhi 39(4): 320-324, 2018

Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy. Japanese Journal of Clinical Hematology 45(10): 1129-1134, 2004

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group. Case Reports in Oncology 2(3): 194-202, 2009

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Japanese Journal Of Cancer Research. 89(7): 748-756, Y, 1998

Chimeric monoclonal anti-CD20 antibody rituximab for the therapy of B-cell non-Hodgkins lymphoma Treatment results and new clinical studies. Annals of Hematology 77(SUPPL 2): S148, 1998

Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkins lymphoma using the monoclonal anti-CD20 antibody rituximab Evaluation of safety and response. Blood 94(10 SUPPL 1 PART 2): 270b, Nov 15, 1999

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkins lymphoma SWOG 9800. Blood 98(11 Part 1): 843a, November 16, 2001